Zoetis launches CircoMax in Europe, the new PCV2 vaccine with two genotypes

Proven to provide biologically superior protection compared to single genotype vaccines


calendar icon June 29, 2023

clock icon
3 minute read

Today Zoetis announced the launch of CircoMax

in Europe. It is the new vaccine for porcine circovirus type 2 (PCV2) which includes two genotypes (a & b), providing broader coverage and protection against the PCV2 threat. CircoMax has demonstrated protection against PCV2a, PCV2b and PCV2d.

PCV2 continues to evolve in pig populations. Initially the PCV2a genotype was the most prevalent, which is why it was the antigen included in commercial vaccines. The virus then progressed to PCV2b, and today PCV2d is the dominant and most frequent genotype. PCV2 has one of the highest mutation rates among DNA viruses. The genotypes are divided into so-called clusters. The PCV2b and PCV2d genotypes belong to the same cluster and are phylogenetically closely related, explained Prof. Heiko Nathues, from the University of Bern.

The vaccine, with its dual genotype, has been shown to provide biologically superior protection compared to a single genotype vaccine.2.3
This could give vets and farmers further assurance that their pigs are well protected against this ever-evolving virus. The new product has been developed for veterinarians and producers in situations where the focus is on PCV2 control. CircoMax is designed to stimulate both cell-mediated and antibody-based immunity, with the goal of providing an immune response similar to that induced by a natural infection. CircusMax It comes in an easy-to-administer, ready-to-use single dose with a duration of immunity (DOI) of 23 weeks. It is formulated with the MetaStim adjuvant and has a demonstrated safety profile as described in the Summary of Product Characteristics (SmPC).

Zoetis now offers both the new CircoMax, together with CircoMax Myco, for effective simultaneous vaccination against PCV2 and Mycoplasma hyopneumoniae, also in ready-to-use single-dose formulation. The swine industry faces ongoing disease-related challenges; our research has consistently shown that, with the PCV2 dual genotype technology in CircoMax and CircoMax Myco, we get broader protection against PCV2, and therefore increases the chances of protection against the ever-evolving PCV2 genotypes by providing a broader umbrella for swine health, said Alvaro Aldaz, Director, Global Business Development, Swine, Zoetis.

Analysis of contemporary strains of PCV2, including multiple isolates from European countries, confirms that CircoMax vaccines offer broader coverage than competing vaccines based on PCV2a alone1, said Jose Angulo, Director, Global Technical Lead Swine, Zoetis. We need to be able to adapt and stay one step ahead of evolving PCV2 genotypes. Our vaccines offer high levels of efficacy, convenience and proven safety according to SPC descriptions. These pig vaccines offer solid long-lasting protection for healthy piglets against advancing threats.

About CircoMax

CircusMax is a veterinary vaccine that contains inactivated recombinant chimeric porcine circovirus type 1 containing porcine circovirus type 2a open reading frame 2 (ORF2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing porcine circovirus type 2b ORF2 protein.

About CircoMax Mico

CircusMax Myco is a veterinary vaccine that contains inactivated recombinant chimeric porcine circovirus type 1 containing porcine circovirus type 2a open reading frame 2 (ORF2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing porcine circovirus type 2b ORF2 protein And Mycoplasma hyopneumoniaestrain P-5722-3.

The efficacy and safety of CircoMax and CircoMax Myco is supported by a comprehensive clinical trial program reviewed by the European Medicines Agency and included in the regulatory process approved by the European Commission.


#Zoetis #launches #CircoMax #Europe #PCV2 #vaccine #genotypes
Image Source : www.thepigsite.com

Leave a Comment